Cite

HARVARD Citation

    Simons, C. et al. (2021). Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. Journal of medical economics. pp. 421-431. [Online]. 
  
Back to record